Taisho/Tanabe
This article was originally published in The Tan Sheet
Executive Summary
Japanese pharmaceutical firms terminate plans to form joint holding company that would have created country's third largest drug maker, Tanabe Seiyaku announces Dec. 3. "Differences regarding the most appropriate direction to be pursued post-merger, in addition to the differences existing in the companies' fundamental infrastructure, makes it unlikely for the companies to be able to take full advantage of their respective strengths and specialties or bring increased value to stockholders," Tanabe states. Under the plan, Taisho - Japan's top OTC producer - would have absorbed Tanabe's OTC business, while Tanabe would have integrated Taisho's Rx operations (1"The Tan Sheet" Sept. 24, In Brief)...
You may also be interested in...
Taisho/Tanabe
Japanese firms' formation of joint holding company will create third largest drug maker in Japan with combined OTC sales of roughly $1.54 bil. Decision reflects "intensifying competition in the pharmaceutical industry" and "rapid changes in the business environment," firms say Sept. 17. Agreement comes on heels of GSK's July deal with Taisho to sell Nicoderm CQ in Japan (1"The Tan Sheet" July 2, In Brief). Companies will join forces April 2002, and by next October, Taisho - Japan's top OTC producer - will absorb Rx leader Tanabe's smaller OTC business; Tanabe will integrate Taisho's Rx operations
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.